Corbus Pharmaceuticals announced the results from the Phase 1a study of CRB-913, showing a favorable safety profile and evidence of weight loss in participants with obesity.
CRB-913 demonstrated safety and tolerability across all doses studied.
Participants on CRB-913 experienced a placebo-adjusted mean weight loss of 2.9% at Day 14 in the dedicated cohort of people with obesity.
Safety Profile
CRB-913 was safe and well-tolerated with no serious adverse events reported in the study.
Weight Loss Effect
Participants treated with CRB-913 experienced a mean 2.9% placebo-adjusted weight loss by Day 14, showing promising results for obesity management.
Neuropsychiatric Assessments
Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participants, indicating stable mental health during the study.
- CRB-913's observed weight loss effect and safety profile provide promising evidence for its potential as a treatment for obesity.
- The initiation of the Phase 1b dose-range finding study 'CANYON-1' signifies the company's commitment to further evaluate CRB-913 in obesity management.
The Phase 1a study results demonstrate the safety and efficacy of CRB-913 in promoting weight loss in participants with obesity, paving the way for future developments in chronic obesity management.